Skip to main content
main-content

medwireNews@

ASH 2019: Expert interviews

10-12-2019 | Haematology | Video

ASH 2019 | Four cycles of R-CHOP confirmed as good approach for limited stage DLBCL

Daniel Persky gives the results of the large National Clinical Trials Network S1001 study, confirming the benefits of four cycles of R-CHOP for PET-negative patients with limited stage diffuse large B-cell lymphoma (2:57).

10-12-2019 | Haematology | Video

ASH 2019 | Triple drug combination with daratumumab shows promise in multiple myeloma

Saad Usmani highlights the phase 3 CANDOR trial findings demonstrating the survival benefits of adding daratumumab to carfilzomib and dexamethasone in the treatment of relapsed or refractory multiple myeloma (4:18).

10-12-2019 | Haematology | Video

ASH 2019 | Blinatumomab superior to chemotherapy after first relapse in young ALL patients

Patrick Brown shares his phase 3 trial findings pitting blinatumomab against chemotherapy as post-reinduction therapy prior to allogeneic hematopoietic stem cell transplant in children and young patients with B-cell acute lymphoblastic leukaemia (4:04).  

09-12-2019 | Haematology | Video

ASH 2019: Clinical benefit with CAR T-cell therapy in mantle cell lymphoma

Brian Hill discusses the phase 2 ZUMA-2 trial looking at the response to KTE-X19 in patients with relapsed or refractory mantle cell lymphoma (3:42).

09-12-2019 | Haematology | Video

ASH 2019 | Mosunetuzumab offers an option beyond CAR T-cell therapy in NHL

Stephen Schuster gives the latest findings on mosunetuzumab showing durable response in poor prognosis patients with non-Hodgkin lymphoma (5:11). 

10-12-2019 | Haematology | Video

ASH 2019 | Dasatinib superior to imatinib in paediatric Philadelphia chromosome-positive ALL

Ching-Hon Pui discusses phase 3 findings showing improved survival with dasatinib versus imatinib given alongside intensive chemotherapy for the treatment of children with Philadelphia chromosome-positive acute lymphoblastic leukaemia (3:47).

09-12-2019 | Haematology | Video

ASH 2019 | ELEVATE TN: Acalabrutinib outperforms chlorambucil in CLL

Jeff Sharman reports findings highlighting improved survival outcomes for treatment-naïve patients with chronic lymphocytic leukaemia taking acalabrutinib versus chlorambucil alongside obinutuzumab (4:13).

08-12-2019 | Video

ASH 2019 | Geriatric assessment helps personalize therapy in older adults with AML

Vijaya Bhatt takes us through his research combining geriatric assessment with genetic profiling to better select precision treatment for individuals with acute myeloid leukaemia (6:48).

08-12-2019 | Haematology | Video

ASH 2019 | Distinct CLL cell populations provide rationale for combining drugs to minimize residual disease

Yue Lynn Wang gives an overview of her team’s chronic lymphocytic leukaemia proliferation model, which has demonstrated the benefits of combining ibrutinib and venetoclax (5:11).

08-12-2019 | Haematology | Video

ASH 2019 | Young AML patients respond well to venetoclax, high-dose chemotherapy combination

Seth Karol talks to us about his study of the B-cell lymphoma 2 inhibitor venetoclax showing a good response when combined with cytarabine in children and young adults with relapsed or refractory acute myeloid leukaemia (3:15).

08-12-2019 | Haematology | Video

ASH 2019 | Short delay from diagnosis to treatment may not be a bad thing in AML

Christoph Röllig reports findings suggesting that waiting for genetic and laboratory test results in order to get the right treatment may be a reasonable approach for clinically stable patients with acute myeloid leukaemia (7:47).

08-12-2019 | Haematology | Video

ASH 2019: CARTITUDE-1: Early and deep response with B-cell maturation antigen in multiple myeloma

Deepu Madduri discusses her trial findings showing a good response to the CAR T-cell therapy JNJ-4528 in multiple myeloma patients with relapsed or refractory disease (2:53).

ESMO 2019: Expert interviews

02-10-2019 | Gastrointestinal cancer | Video

ESMO 2019: Potential of targeted therapy for cholangiocarcinoma shown in ClarIDHy trial

Ghassan Abou-Alfa takes us through the ClarIDHy results, which suggest that ivosidenib could be an option for IDH1-mutated, advanced cholangiocarcinoma (3:37).

01-10-2019 | Urothelial cancer | Video

ESMO 2019: Atezolizumab shows promise in advanced urothelial cancer

Enrique Grande presents the IMvigor130 trial assessing front-line atezolizumab, either as monotherapy or alongside chemotherapy, in treatment-naïve individuals with locally advanced or metastatic urothelial carcinoma (5:54).

30-09-2019 | Breast cancer | Video

ESMO 2019: KEYNOTE-522 points to pembrolizumab role in triple-negative breast cancer

Peter Schmid discusses data pointing to a role for pembrolizumab in the neoadjuvant and adjuvant treatment of newly diagnosed, early-stage triple-negative breast cancer (3:32).

30-09-2019 | Breast cancer | Video

ESMO 2019: MONALEESA-3 OS results demonstrate ribociclib–fulvestrant benefit

Dennis Slamon outlines the MONALEESA-3 findings showing that postmenopausal women with HR-positive, HER2-negative advanced breast cancer derive a survival advantage from combining the CDK4/6 inhibitor ribociclib with fulvestrant (1:47).

29-09-2019 | Breast cancer | Video

ESMO 2019: MONARCH 2 update – OS gain with abemaciclib plus fulvestrant

George Sledge Jr reports overall survival data for the MONARCH 2 trial investigating the addition of the CDK4/6 inhibitor abemaciclib to fulvestrant in women with HR-positive, HER2-negative metastatic breast cancer (2:49).

29-09-2019 | Gynaecological cancer | Video

ESMO 2019: PAOLA-1 supports maintenance olaparib plus bevacizumab for newly diagnosed advanced ovarian cancer

Adding a PARP inhibitor to maintenance bevacizumab therapy improves progression-free survival for advanced ovarian cancer regardless of BRCA mutation status (1:41).

ASCO 2019 Expert interviews

04-06-2019 | Breast cancer | Video

ASCO 2019: Low-fat diet linked to reduced risk of breast cancer mortality

Rowan Chlebowski discusses the latest update from the Women’s Health Initiative Dietary Modification clinical trial showing the positive impact of a healthy diet on the risk of breast cancer death in postmenopausal women. He also touches upon how the metabolic syndrome may modify this risk (5:52).

04-06-2019 | Prostate cancer | Video

ASCO 2019: Enzalutamide addition prolongs survival in metastatic CSPC setting

Ian Davis takes us through the potentially practice-changing results of the phase III ENZAMET trial evaluating the addition of enzalutamide to standard of care in men with castration-sensitive prostate cancer (3:04).

03-06-2019 | Gastrointestinal cancer | Video

ASCO 2019: Olaparib maintenance improves BRCA1/2-positive pancreatic cancer outcomes

Hedy Kindler presents the phase III POLO trial of maintenance therapy with the PARP inhibitor olaparib in metastatic pancreatic cancer patients harbouring germline mutations in BRCA1 or BRCA2 (3:47).

03-06-2019 | Gastrointestinal cancer | Video

ASCO 2019: Low-dose chemotherapy a valid option for older gastro-oesophageal cancer patients

Peter Hall reports on the GO2 trial that aimed to optimise chemotherapy with oxaliplatin and capecitabine in elderly and frail individuals with advanced gastro-oesophageal cancer (1:40).

02-06-2019 | Breast cancer | Video

ASCO 2019: Ribociclib addition boosts OS in premenopausal advanced breast cancer patients

Sara Hurvitz summarises the findings of the phase III MONALEESA-7 trial investigating the addition of ribociclib to endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer (3:21).

02-06-2019 | Prostate cancer | Video

ASCO 2019: TITAN shows survival benefit with apalutamide in metastatic CSPC

Anders Bjartell outlines the main results of the placebo-controlled TITAN trial of apalutamide in men with castration-sensitive prostate cancer receiving androgen deprivation therapy (2:19).

SABCS 2018: Expert interviews

07-12-2018 | Breast cancer | Video

PD-L1 in immune cells predicts atezolizumab plus nab-paclitaxel efficacy in metastatic triple-negative breast cancer

Presenting author Leisha Emens outlines exploratory efficacy analysis results from IMpassion130 showing that programmed cell death ligand 1 in immune cells is a robust predictive biomarker for selecting women with metastatic triple-negative breast cancer who may benefit from first-line atezolizumab plus nab-paclitaxel treatment (6:19).

07-12-2018 | Breast cancer | Video

Circulating tumour cell count could aid first-line hormone versus chemotherapy treatment decisions

Francois-Clement Bidard reports findings that circulating tumour cell count could help oncologists choose between first line hormone therapy and chemotherapy in women with oestrogen receptor positive, HER2-negative metastatic breast cancer (3:23).

07-12-2018 | Breast cancer | Video

Achieving pCR after neoadjuvant chemotherapy improves event-free and overall survival

Aditya Bardia explains the importance of research done by him and his colleagues validating pCR as a robust surrogate biomarker for outcomes particularly in women with triple negative and HER2-positive breast cancer (5:26).  

06-12-2018 | Breast cancer | Video

Impact of breast cancer surgery on quality of life

Ann Partridge discusses the E5103 study findings regarding the quality of life issues faced by women undergoing mastectomy and the need to continue monitoring them long term (5:14).

07-12-2018 | Breast cancer | Video

Delayed initiation of adjuvant chemotherapy significantly impacts survival in women with triple-negative breast cancer

Presenting author Zaida Morante discusses findings showing that the greater the delay in initiating adjuvant chemotherapy the worse a woman’s outcome in terms of overall and disease-free survival (2:59).

06-12-2018 | Breast cancer | Video

Study TAM01: Low-dose tamoxifen prevents breast intraepithelial neoplasia recurrence

Andrea DeCensi outlines his study findings demonstrating that low-dose tamoxifen 5 mg/day significantly lowers the recurrence of intraepithelial neoplasia versus placebo without increasing endometrial cancer and deep vein thrombosis (3:32).

06-12-2018 | Breast cancer | Video

Radiotherapy comparable to axillary lymph node dissection for locoregional control in breast cancer patients with a positive sentinel lymph node

Emiel Rutgers gives an overview of the 10-year follow-up results from the EORTC AMAROS trial demonstrating that radiotherapy has equivalent locoregional control to that of axillary lymph node dissection  but with a reduced risk of lymphedema (4:28).

06-12-2018 | Breast cancer | Video

KATHERINE trial: Adjuvant trastuzumab emtansine improves invasive disease-free survival versus trastuzumab after neoadjuvant chemotherapy in HER2-positive women

Charles Geyer reports his phase III study findings showing the potential for adjuvant trastuzumab emtansine as a new standard of care in women with HER-2 positive, early breast cancer and residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy (7:56).

06-12-2018 | Breast cancer | Video

Accelerated partial versus whole breast irradiation for controlling ipsilateral breast tumour recurrence

Frank Vicini discusses his research showing that while partial breast irradiation after lumpectomy is not equivalent to whole breast irradiation for long-term control of ipsilateral breast tumour recurrence, the difference is small (2:27). 

ASH 2018: Expert interviews

05-12-2018 | Leukaemia | Video

Quantum-R trial looks at efficacy of quizartinib in AML patients

Jorge Cortes outlines the findings from the Quantum-R trial of quizartinib in patients with relapsed/refractory acute myeloid leukaemia with a FLT3-internal tandem duplication and a poor prognosis (5:58).

04-12-2018 | Lymphoma | Video

Two-year follow-up and high-risk subset analysis of ZUMA-1

Frederick Locke discusses long-term follow-up results from the ZUMA-1 trial, demonstrating high rates of durable response to axicabtagene ciloleucel treatment among patients with refractory large B-cell lymphoma (4:28).

04-12-2018 | Oncology | Video

Prophylactic treatment with rivaroxaban reduces cancer patients' VTE risk

Study author Alok Khorana discusses the results of the CASSINI trial, demonstrating a reduction in venous thromboembolism during treatment with rivaroxaban among patients with cancer (2:54).

04-12-2018 | Leukaemia | Video

BCL2 gene mutation confers resistance to venetoclax treatment in CLL patients

Piers Blombery comments on his study results demonstrating that the BCL2 Gly101Val mutation impairs binding of venetoclax to BCL2, leading to an increased risk of chronic lymphocytic leukaemia progression during treatment (2:56).

04-12-2018 | Lymphoma | Video

Sustained disease control with tisagenlecleucel in refractory DLBCL setting

Richard Maziarz takes us through the long-term follow-up results of the JULIET trial indicating that the CAR T-cell therapy tisagenlecleucel has achieved a high response rate and enduring responses in adults with relapsed or refractory diffuse large B-cell lymphoma (6:38).

04-12-2018 | Lymphoma | Video

Reducing chemotherapy in younger diffuse large B-cell lymphoma patients

Viola Poeschel outlines findings from the FLYER trial, showing that a six-cycle R-CHOP plus rituximab regimen can be reduced to four cycles of R-CHOP plus rituximab without compromising efficacy in younger patients with diffuse large B-cell lymphoma and a favourable prognosis (4:33).

03-12-2018 | Chronic myeloid leukaemia | Video

EUTOS long-term survival score recommended over Sokal score for elderly CML patients

Presenting author Fausto Castagnetti discusses the results of their study assessing the best score to predict outcomes in older patients with chronic myeloid leukaemia (4:17).

ESMO 2018: Expert interviews

24-10-2018 | Head and neck cancer | Video

KEYNOTE-048: Phase III study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma

Barbara Burtness talks through the results of the KEYNOTE-048 trial comparing pembrolizumab alone or with chemotherapy versus the EXTREME regimen for patients with recurrent or metastatic head and neck cancer (5:10).

24-10-2018 | Breast cancer | Video

PALOMA-3 defines a new standard of care for advanced breast cancer

Massimo Cristofanilli discusses the latest results from the PALOMA-3 trial investigating the addition of the CDK4/6 inhibitor palbociclib to fulvestrant in previously treated advanced breast cancer (5:21).

24-10-2018 | Head and neck cancer | Video

De-ESCALaTE HPV results revealed

Hisham Mehanna describes the results of the De-ESCALaTE HPV  trial comparing cetuximab versus cisplatin for the treatment of low-risk oropharyngeal cancer patients undergoing radiotherapy (5:43).

24-10-2018 | Breast cancer | Video

IMpassion130 survival results

Peter Schmid discusses the progression-free and interim overall survival results for atezolizumab plus nab-paclitaxel in the setting of metastatic triple-negative breast cancer (5:24).

ASCO 2018: Expert interviews

06-06-2018 | Genetics | Video

Matching treatment to molecular alterations in tumors has an IMPACT on survival

Apostolia Tsimberidou discusses the findings of the IMPACT study, looking at the survival benefits of matching targeted treatments to the genetic alterations of tumors across multiple cancer types (7:56).

05-06-2018 | Kidney cancer | Video

CARMENA trial of cytoreductive nephrectomy in renal cell carcinoma

Arnaud Méjean presents the CARMENA trial findings, suggesting that cytoreductive nephrectomy may no longer be the standard of care for metastatic renal cell carcinoma in the era of sunitinib (4:21).

05-06-2018 | Breast cancer | Video

TAILORx trial in breast cancer

Joseph Sparano gives an overview of his team's findings regarding a 21-gene prognostic test that could help tailor treatment for women with early breast cancer (3:24).

04-06-2018 | Prostate cancer | Video

Abi Race: abiraterone acetate and prednisone treatment in Black and White men with prostate cancer

Lead author Daniel George discusses his findings of a greater and longer lasting treatment effect with abiraterone acetate and prednisone in Black than White men with metastatic castration-resistance prostate cancer (3:59).

Image Credits